Phase 3 Interstitial Lung Disease Trial, Not Yet Recruiting NCT07668895 Sponsor: Peking Union Medical College Hospital Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 3 Interstitial Lung Disease Trial, Not Yet Recruiting

NCT07668895
Not Yet Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with pulmonary sarcoidosis (a lung condition) within the past 3 months, and it is at an early stage (stage I or II based on a chest scan)
  • Your diagnosis was confirmed through a tissue sample (biopsy) taken during a bronchoscopy (a procedure to look inside the airways)
  • Your chest scan shows swollen lymph nodes in the chest area, with or without other changes in the lungs
  • Your stage of disease was confirmed by at least two independent medical experts who reviewed your chest scans
  • Your doctors have decided you need steroid treatment for your condition
  • You are able to attend all the required follow-up appointments during the study
  • You and your family understand the study, are willing to take part, and can sign a consent form

Who may not be able to join:

  • You or your family are unable to understand what the study involves or are unable to sign a consent form
  • You are unable to attend the required check-up appointments as set out by the study
  • You have other serious health conditions that, in the doctor's opinion, could affect your safety or ability to follow the study rules
  • You have significant abnormal test results that, in the doctor's opinion, could make it hard to assess your safety during the study
  • You are pregnant, breastfeeding, or unable to use reliable contraception during the study and for 3 months after it ends
  • You currently have an active cancer that requires treatment such as surgery, medication, or radiotherapy
  • You have had an allergic reaction to either Diprospan (a steroid medication) or prednisone (another steroid medication)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86+13391587917

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 July 2026
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline in percent predicted FVC after 24 weeks of treatment (%)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov